Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES, INC.ARE · Entity 419 | Director · Executive Chairman | September 11, 2026 | September 15, 2026 |
| Applied Therapeutics, Inc.APLT · Entity 67708 | Director | June 06, 2024 | June 07, 2024 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | March 15, 2019 | March 19, 2019 |
| Korro Bio, Inc.FREQ · Entity 6388 | Director | August 17, 2022 | August 19, 2022 |
| MeiraGTx Holdings plcMGTX · Entity 4734 | Director | June 07, 2022 | June 09, 2022 |
| TRex Bio, Inc.TRXB · Entity 184308 | Director | October 13, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXANDRIA REAL ESTATE EQUITIES, INC.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 597,724 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Purchase · Acquired 5,000 · Balance 597,724 F1: The shares were purchased at prices ranging from $49.38 to $49.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased at prices ranging from $49.38 to $49.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Applied Therapeutics, Inc.
Report date June 06, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 498,414 |
Reported balance
After 2024-06-06 transaction · row 1
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 45,000 · Balance 498,414 F1: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date.
Atara Biotherapeutics, Inc.
Report date March 15, 2019 · Filed March 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 888,355 |
Reported balance
After 2019-03-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-03-15 · Sale · Disposed 20,000 · Balance 888,355 F1: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $38.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by the Joel S. Marcus and Barbara A. Marcus Family Trust | 4,000 |
Reported balance
Holding disclosure · report date 2019-03-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 |
| Common StockSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2019-03-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $38.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein.
Korro Bio, Inc.
Report date August 17, 2022 · Filed August 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2030-06-10 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $18.63 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-06-16 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.14 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders
F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders
F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
MeiraGTx Holdings plc
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.25 · Expires 2032-06-07 | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F2: Each restricted share unit converts into one ordinary share upon vesting. F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
F2: Each restricted share unit converts into one ordinary share upon vesting.
F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
TRex Bio, Inc.
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,871 |
Reported balance
After 2026-10-13 transaction · row 1
1 source rowRow 1 · 2026-10-13 · Conversion · Acquired 41,871 · Balance 41,871 F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-13 · Conversion · Disposed 161,828 · Balance 0 F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intra-Cellular Therapies, Inc.
Report date April 02, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 1
1 source rowRow 1 · 2025-04-02 · Disposition to issuer · Disposed 48,238 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-04-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F3: Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
F3: Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
F6: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share.
F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.
F8: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2018 Filed Aug 6, 2018 20:23 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 29,500 | $126.87 | $3,742,665.00 |
DisclosureSEC source: 0001035443-18-000163 · wf-form4_153358702073247.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,255 F1 · price: The shares were sold at prices ranging from $126.66 to $127.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 18, 2018 Filed Jun 20, 2018 20:49 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantRestricted Stock Units · Derivative | 14,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038795 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,189 Underlying: Common Stock · 14,189 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019). F2 · derivative.expiration_date: On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019). Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-18-038314 · doc4.xml · derivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-13 F3 · derivative.exercise_date: The option shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 20:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038314 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · shares: These restricted stock units shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| June 14, 2018 Filed Mar 1, 2019 21:08 UTC Amendment | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-19-014938 · doc4a.xml · derivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-13 F3 · derivative.exercise_date: The option shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| June 14, 2018 Filed Mar 1, 2019 21:08 UTC Amendment | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014938 · doc4a.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · shares: These restricted stock units shall vest on June 14, 2019, subject to the Reporting Person's continuous service. Read SEC document |
| May 10, 2018 Filed May 14, 2018 20:43 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 13,000 | $130.00 | $1,690,000.00 |
DisclosureSEC source: 0001035443-18-000100 · wf-form4_152633057936486.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,755 F1 · price: The shares were sold at prices ranging from $130.00 to $130.11. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 08, 2018 Filed May 9, 2018 20:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 15,000 | $128.52 | $1,927,800.00 |
DisclosureSEC source: 0001035443-18-000097 · wf-form4_152589825420020.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624,755 F2 · price: The shares were sold at prices ranging from $128.36 to $128.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2018 Filed May 9, 2018 20:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $128.56 | $642,800.00 |
DisclosureSEC source: 0001035443-18-000097 · wf-form4_152589825420020.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 639,755 F1 · price: The shares were sold at prices ranging from $128.46 to $128.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2018 Filed May 7, 2018 20:43 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 12,000 | $127.84 | $1,534,080.00 |
DisclosureSEC source: 0001035443-18-000090 · wf-form4_152572578172237.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,755 F2 · price: The shares were sold at prices ranging from $127.77 to $127.92. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:43 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 13,000 | $127.17 | $1,653,210.00 |
DisclosureSEC source: 0001035443-18-000090 · wf-form4_152572578172237.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,755 F1 · price: The shares were sold at prices ranging from $127.15 to $127.27. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 21:31 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-18-000050 · wf-form4_152270465862139.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,755 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:24 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $120.86 | $604,300.00 |
DisclosureSEC source: 0001035443-18-000032 · wf-form4_151916182967877.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,755 F1 · price: The shares were sold at prices ranging from $120.84 to $120.89. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 21:32 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $124.75 | $623,750.00 |
DisclosureSEC source: 0001035443-18-000030 · wf-form4_151786633720729.xml · nonDerivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,755 Read SEC document |
| February 02, 2018 Filed Feb 5, 2018 21:32 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $123.62 | $618,100.00 |
DisclosureSEC source: 0001035443-18-000030 · wf-form4_151786633720729.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,755 Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:32 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 11,603 | $126.23 | $1,464,646.69 |
DisclosureSEC source: 0001035443-18-000030 · wf-form4_151786633720729.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,755 F2 · price: The shares were sold at prices ranging from $126.15 to $126.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 21:32 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 8,397 | $125.58 | $1,054,495.26 |
DisclosureSEC source: 0001035443-18-000030 · wf-form4_151786633720729.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,358 F1 · price: The shares were sold at prices ranging from $125.20 to $126.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 21:27 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 55,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-18-000003 · wf-form4_151613805446816.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679,755 Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:39 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 27,500 | $129.60 | $3,564,000.00 |
DisclosureSEC source: 0001035443-17-000193 · wf-form4_151259633802456.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,936 F1 · price: The shares were sold at prices ranging from $129.43 to $130.06. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 30, 2017 Filed Dec 4, 2017 21:36 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 13,000 | $126.91 | $1,649,830.00 |
DisclosureSEC source: 0001035443-17-000190 · wf-form4_151242339987466.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 651,436 F1 · price: The shares were sold at prices ranging from $126.81 to $127.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 20:37 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 25,000 | $118.99 | $2,974,750.00 |
DisclosureSEC source: 0001035443-17-000157 · wf-form4_150654461640997.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664,436 F1 · price: The shares were sold at prices ranging from $118.82 to $119.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 20:47 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 15,500 | $121.16 | $1,877,980.00 |
DisclosureSEC source: 0001035443-17-000149 · wf-form4_150300281741183.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,436 F1 · price: The shares were sold at prices ranging from $120.91 to $121.39. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 20:28 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 893 | $122.03 | $108,972.79 |
DisclosureSEC source: 0001035443-17-000143 · wf-form4_150213768783405.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,936 F2 · price: The shares were sold at prices ranging from $122.00 to $122.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 03, 2017 Filed Aug 7, 2017 20:28 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 13,000 | $121.16 | $1,575,080.00 |
DisclosureSEC source: 0001035443-17-000143 · wf-form4_150213768783405.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,829 F1 · price: The shares were sold at prices ranging from $121.05 to $121.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 20:22 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $12.45 | $0.00 |
DisclosureSEC source: 0001209191-17-042293 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 21,500 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001209191-17-039238 · doc4.xml · derivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2024-06-08 F3 · derivative.exercise_date: The option shall vest on June 8, 2018, subject to the Reporting Person's continuous service. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039238 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 F1 · shares: These restricted stock units shall vest on June 8, 2018, subject to the Reporting Person's continuous service. Read SEC document |
| May 10, 2017 Filed May 12, 2017 20:33 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $114.77 | $573,850.00 |
DisclosureSEC source: 0001035443-17-000097 · wf-form4_149462121214527.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,829 F1 · price: The shares were sold at prices ranging from $114.75 to $114.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:21 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 14,000 | $112.92 | $1,580,880.00 |
DisclosureSEC source: 0001035443-17-000090 · wf-form4_149427484459284.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,829 F1 · price: The shares were sold at prices from $112.87 to $113.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:30 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 30,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-17-000060 · wf-form4_149133782758915.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 737,829 Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 20:30 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 9,500 | $110.37 | $1,048,515.00 |
DisclosureSEC source: 0001035443-17-000045 · wf-form4_149012819073718.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 707,619 F1 · price: The shares were sold at prices from $110.36 to $110.41. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 07, 2017 Filed Feb 8, 2017 21:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 1,500 | $113.40 | $170,100.00 |
DisclosureSEC source: 0001035443-17-000028 · wf-form4_148658989188098.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,119 F2 · price: The shares were sold at prices from $113.39 to $113.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 21:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $112.36 | $561,800.00 |
DisclosureSEC source: 0001035443-17-000028 · wf-form4_148658989188098.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,619 F1 · price: The shares were sold at prices from $112.34 to $112.43. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2017 Filed Feb 3, 2017 21:10 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 13,000 | $108.52 | $1,410,760.00 |
DisclosureSEC source: 0001035443-17-000025 · wf-form4_148615621275456.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,619 F1 · price: The shares were sold at prices from $108.25 to $108.83. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 30, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftCommon Stock | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · nonDerivative · entry 9 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 110,742 F1 · kind: On January 30, 2017, the aggregate of 95,000 shares of common stock acquired by Mr. Marcus upon the exercise of stock options was transferred for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. Read SEC document |
| January 30, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftCommon Stock | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · nonDerivative · entry 8 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,671 F1 · kind: On January 30, 2017, the aggregate of 95,000 shares of common stock acquired by Mr. Marcus upon the exercise of stock options was transferred for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · derivative · entry 18 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2017-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · derivative · entry 17 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2018-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · derivative · entry 16 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2020-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · derivative · entry 15 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2020-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · derivative · entry 14 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · derivative · entry 13 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2023-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · derivative · entry 12 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2023-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 12,500 | $1.50 | $18,750.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · nonDerivative · entry 7 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 12,500 | $1.50 | $18,750.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · nonDerivative · entry 6 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 12,500 | $2.74 | $34,250.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · nonDerivative · entry 5 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 12,500 | $2.74 | $34,250.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · nonDerivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 12,500 | $2.84 | $35,500.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 12,500 | $3.26 | $40,750.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2017 Filed Jan 30, 2017 23:13 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 20,000 | $3.26 | $65,200.00 |
DisclosureSEC source: 0001209191-17-006207 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.